CNBC's Courtney Reagan looks ahead to what are likely to be next week's top business and financial stories. » Read More
Tesla Motors has won U.S. antitrust approval to buy solar panel installer SolarCity, the Federal Trade Commission said on Thursday.
Canberra’s rejection of the sale Ausgrid was the “correct decision” on grounds of national interests, a former Aussie DPM said.
Ad-tech company Media.net's CEO Divyank Turakhia tells CNBC why the $900 million acquisition deal by a group of Chinese investors made sense.
AstraZeneca has agreed to sell its small molecule antibiotics business to Pfizer in a deal that could be valued at more than $1.5 billion.
India's third-largest telecommunications company Idea Cellular is exploring a strategic deal with rival Vodafone India, CNBC-TV18 reported.
Baltic Exchange CEO Jeremy Penn says there is great future opportunities for the Baltic Exchange with the SGX deal.
The deal makes sense because SGX's fastest-growing business is in commodity derivatives, shares SGX's Head of Derivatives Michael Syn.
Tech companies are investing time and money into products that will keep consumers begging for more.
Debt is cheap, markets are high and bankers are expecting more big M&A to close out the year.
Alex Tarrant, assistant editor at Dealreporter Europe, Mergermarket Group, shares his views on the deal between Pfizer and Medivation.
Pharmaceutical firms rely on acquisitions to plug the gap on innovations they do not currently possess, says Albert Fried and Company's Sachin Shah.
Pfizer investors should be concerned about the high premium, while Medivation investors should celebrate, says RBC Capital Markets' Simos Simeonidis.
CNBC's Meg Tirrell reports on the action in the IBB biotech ETF after Pfizer announced it was buying Medivation and what some other big M&A deals could be coming down the line. The "Fast Money" traders weigh in.
CNBC's Meg Tirrell reports the details on Pfizer's deal for Medivation.
Biotech stocks have underperformed the market but that could change as investors bet more deals could be in the making.
Boutique banks are taking more deal flow from the biggest firms on the Street.
Get the best of CNBC in your inbox